Biotech Values

[turtlepower]

ACHN - FWIW I don't think the offering means they may go it alone on 1625. Their pipeline indicates they have other early stage HCV candidates to spend the money on. Their HIV and bacterial infection drugs are essentially dead aren't they? If they restart one or more of the dormant drugs the cash from the offering may not last that long.